{"schema_version":"secwatch.filing_event.v1","accession":"0001935979-26-000080","form_type":"8-K","ticker":"BHVN","cik":"0001935979","company_name":"Biohaven Ltd.","filed_at":"2026-10-15T21:18:55+00:00","discovered_at":"2026-10-15T21:20:00.325171+00:00","generated_at":"2026-10-15T21:20:07.321960+00:00","sec_items":["1.01","7.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Biohaven licenses MoDE IgG degraders to Ono for $80M upfront, up to $100M near-term, ~20% royalties in Asia","bullets":["Ono gets exclusive rights to develop/commercialize BHV-1300, BHV-1310, BHV-1320 in Japan, South Korea, Taiwan, and ASEAN; Biohaven retains US, Europe, China rights.","Deal: $80M upfront at closing, $20M milestone anticipated within a year, ~20% royalties on net sales; Ono funds specified territory activities and shares global study costs.","BHV-1300 is in Phase 3 for Graves' disease; Phase 1b showed deep reduction in TSH-receptor autoantibody, normalized free T3/T4, IgG3 sparing.","Up to 87% total IgG reduction observed in Phase 1 studies; autoinjector self-administration; potential first-in-class extracellular IgG degrader.","J.P. Morgan is financial advisor; Sullivan & Cromwell legal advisor. Ono ticker TYO:4528; agreement dated Oct 8, 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001935979-26-000080","json":"https://secwatch.observer/filing/0001935979-26-000080.json","markdown":"https://secwatch.observer/filing/0001935979-26-000080.md","text":"https://secwatch.observer/filing/0001935979-26-000080.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1935979/000193597926000080/0001935979-26-000080-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1935979/000193597926000080/bhvn-20261008.htm"},"model":{"generated_by":"deepseek-v4.1-flash:cloud@v2","generated_at":"2026-10-15T21:20:07.321960+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}